Takeda Pharmaceutical Company Limited

BOVESPA:TAKP34 Voorraadrapport

Marktkapitalisatie: R$259.7b

Takeda Pharmaceutical Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Takeda Pharmaceutical has been growing earnings at an average annual rate of 10.3%, while the Pharmaceuticals industry saw earnings growing at 6.2% annually. Revenues have been growing at an average rate of 8.2% per year. Takeda Pharmaceutical's return on equity is 4.2%, and it has net margins of 6.4%.

Belangrijke informatie

10.3%

Groei van de winst

10.0%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie12.4%
Inkomstengroei8.2%
Rendement op eigen vermogen4.2%
Nettomarge6.4%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Takeda Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

BOVESPA:TAKP34 Opbrengsten, kosten en inkomsten (JPY Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 244,546,083289,9961,091,066725,957
30 Jun 244,413,134149,9201,075,736734,339
31 Mar 244,263,762144,0671,053,819728,617
31 Dec 234,169,049178,2191,023,306695,012
30 Sep 234,154,414191,6261,018,085682,260
30 Jun 234,113,631301,3981,013,867652,459
31 Mar 234,027,478317,017997,234633,325
31 Dec 223,944,611274,525965,908616,009
30 Sep 223,749,354213,167934,687569,758
30 Jun 223,591,868197,389897,964547,214
31 Mar 223,569,006230,059886,327526,087
31 Dec 213,465,991438,515897,171495,680
30 Sep 213,401,450473,105888,737484,868
30 Jun 213,345,565431,178892,983471,424
31 Mar 213,197,812376,005875,514455,765
31 Dec 203,199,240180,631895,464486,660
30 Sep 203,221,80456,051921,830491,903
30 Jun 203,243,917119,743928,229486,343
31 Mar 203,291,18844,241964,268492,088
31 Dec 193,236,69713,275965,530485,736
30 Sep 192,876,78283,262867,314440,388
30 Jun 192,496,51163,959790,113407,257
31 Mar 192,097,224135,192692,728368,257
31 Dec 181,780,976110,414608,443317,675
30 Sep 181,769,726140,738616,726321,777
30 Jun 181,772,125120,339622,667321,719
31 Mar 181,770,531186,886628,106325,441
31 Dec 171,785,773190,172632,833324,485
30 Sep 171,762,667163,457622,191314,755
30 Jun 171,746,286160,202616,779310,763
31 Mar 171,732,051114,940615,867311,625
31 Dec 161,729,967132,194614,187312,149
30 Sep 161,754,130150,081627,784332,841
30 Jun 161,795,088155,110633,600337,807
31 Mar 161,807,37880,166650,336335,704
31 Dec 151,831,096-111,874650,103386,767
30 Sep 151,830,521-152,827642,957386,950
30 Jun 151,812,971-154,591637,726387,932
31 Mar 151,777,824-145,775612,489367,741
31 Dec 141,744,79575,405474,242356,593
30 Sep 141,714,694103,390497,474342,907
30 Jun 141,692,531110,981522,831339,169
31 Mar 141,691,685106,658556,210341,560
31 Dec 131,655,033103,3301,036,83110,620

Kwaliteitswinsten: TAKP34 has a large one-off loss of ¥245.4B impacting its last 12 months of financial results to 30th September, 2024.

Groeiende winstmarge: TAKP34's current net profit margins (6.4%) are higher than last year (4.6%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: TAKP34's earnings have grown by 10.3% per year over the past 5 years.

Versnelling van de groei: TAKP34's earnings growth over the past year (51.3%) exceeds its 5-year average (10.3% per year).

Winst versus industrie: TAKP34 earnings growth over the past year (51.3%) exceeded the Pharmaceuticals industry 7.3%.

Rendement op eigen vermogen

Hoge ROE: TAKP34's Return on Equity (4.2%) is considered low.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y